New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2
30.11.2020 11:00:00 EET | Business Wire | Press release
New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is “an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.” This conclusion is “validated by two independent sets of experiments, performed by different labs, on different viral strains...” The Virucidal studies were independently funded.
“The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic,” said Dr. Gustavo Ferrer, who is leading the research team.
State of scientific research:
Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19. Research shows COVID-19 primarily infects and spreads through the upper respiratory system. By reducing viral load in the nose, nasal sprays help limit the severity and transmission of SARS-CoV-2 (COVID-19). https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627.
Xlear’s components are antiviral—they block viral adhesion in the nose. See, for example, https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full.pdf. This Univ. of Tennessee study on SARS-CoV-2 concluded: “antiviral nasal sprays...contribute reduce...viral load...slowing down disease progression...and transmission...”
Peer-reviewed case studies indicate Xlear helps in treating COVID-19: First-look trial at Larkin Community Hospital (Miami), determined: “symptomatic, COVID-19 patients, treated with [Xlear], as an adjunct to...[standard care],” showed “rapid clinical improvement and shorten[ed] time” to negative COVID-19 PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series.
Xlear has been used for over 20 years by millions of people worldwide without a single significant adverse incident report.
“Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2). This combination of antiviral and virucidal capabilities is an important one-two punch in fighting the virus,” said Nathan Jones, CEO of Xlear. “With the pandemic raging worldwide, we must use every tool we can to fight it. Failing that needlessly risks millions of lives. Weighing our 20-year safety record, against the risks of this deadly virus, it’s clear Xlear needs to be in widespread use,” Jones concluded.
Full study: https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
More information on Xlear: https://xlear.com/
About Dr. Gustavo Ferrer
Dr. Ferrer, MD FCCP, is an Associate Professor of Medicine and Founder of the Cleveland Clinic Florida Interstitial Lung Disease Clinic and the Aventura Hospital Pulmonary and Critical Care fellowship. He currently serves as President of Intensive Care Experts/Aventura Pulmonary Institute and previously served as United Nations University Director of Respiratory Research, Venezuela.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005291/en/
Contact information
Jeff Gulko
617.304.7339
jeff@thegulkogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estonia and Owkin Partner to Advance Sovereign AI in Biology29.9.2026 09:00:00 EEST | Press release
Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metrosert, Estonia’s state-owned applied research organisation. The collaboration will evaluate how K Pro, Owkin’s AI scientist platform, can help approved researchers work with complex Estonian health data inside secure national infrastructure, enabling reproducible analysis, and faster generation of scientific insight while preserving data sovereignty. The first phase will focus on selected Estonian health-data cohorts, with Owkin and Metrosert also exploring high-value research areas including oncology, where linked clinical, molecular, imaging and treatment-outcome data could support future biomedical research. Estonia has built one of the world’s most advanced digital public infrastructures and holds population-scale health and biomedical data assets. The partnership will explore how these foundations can
Freemarket and Axiym launch LIQUI-DT™ – real-time business access to primary-market USD₮ from Tether29.9.2026 09:00:00 EEST | Press release
Freemarket and Axiym today launched a world-first service that gives businesses 24/7 real-time access to freshly minted, primary-market USD₮ issued by Tether. LIQUI-DTTM gives businesses compliant access to primary market stablecoins inside a fully regulated payment ecosystem via Freemarket’s global payment network. In audited trials, clients have minted or burned more than $300 million to date. Institutional users and high-volume traders will benefit from superior price certainty and direct liquidity giving them budgetary control. As the USD₮ is minted directly in the primary market, treasury and compliance teams have clear provenance for internal reporting 1. The LIQUI-DT service works because while no single party owns the whole stack, it is integrated into the Freemarket network. The combination of Freemarket’s compliant fiat rails and payment network, Axiym’s liquidity engine and on-chain settlement layer and Tether’s primary market issuance creates a regulated payments network wi
Jumio Completes Worldwide Rollout of selfie.DONE™, Bringing Privacy-Focused Reusable Identity to EMEA29.9.2026 08:00:00 EEST | Press release
Jumio, the leading provider of AI-powered identity intelligence, today announced the expansion of its reusable identity solution, selfie.DONE, across Europe, the Middle East, and Africa. This launch marks the final phase of Jumio’s selfie.DONE rollout, following successful launches in Latin America, North America, and Asia-Pacific — making true reusable identity available worldwide wherever Jumio operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928989719/en/ In regulated EMEA markets, organizations face the dual challenge of eliminating onboarding friction while adhering to stringent privacy standards and regulatory frameworks, including GDPR, PSD2, AMLD, and other evolving regulatory compliance requirements. selfie.DONE addresses this challenge with a privacy-focused, consent-based architecture. Instead of forcing enrolled users through repetitive ID document scans, selfie.DONE establishes a selfie-first fast lan
Lumo Art & Tech Festival Announces Full Programme, Featuring Björk29.9.2026 08:00:00 EEST | Press release
Lumo Art & Tech festival, a new ten-day international festival exploring the intersection of art, technology and science, has announced its full programme for its inaugural edition in Oulu, Northern Finland, as part of the Oulu2026 European Capital of Culture year. Taking place across 16 cultural venues and outdoor locations, the festival brings together exhibitions, light and sound art, audiovisual performances, talks and professional events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928733910/en/ Björk. Credit: Vidar Logi A key highlight is an exhibition by Icelandic artist and musician Björk, opening on 13 November. Following its debut in Reykjavík, the exhibition brings three audiovisual installations to Oulu’s Pekuri Shopping Centre: Ancestress, Sorrowful Soil and Björk Orkestral. Björk will also perform a special DJ set at the new waterfront venue Tarkastamo on 15 November. The festival’s wider programme brings
Copeland to Showcase Solutions for Data Centers, Heat Pumps and Sustainable Refrigeration at Chillventa29.9.2026 08:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced its participation at Chillventa 2026, taking place Oct. 13-15 in Nuremberg, Germany. From growing data center cooling demands to increased adoption of heat pumps and natural refrigerants, customers across Europe are navigating rapid change. Copeland will showcase technologies designed to address the region's evolving heating, cooling and refrigeration requirements. As demand for energy-efficient cooling, electrified heating and sustainable industrial operations grows across Europe, Copeland continues to invest in the technologies, capabilities and partnerships needed to help customers navigate changing regulatory requirements and work toward their sustainability objectives. Copeland has made a series of strategic investments to support Europe's long-term energy and climate priorities. These include the acquisition of Germany-based SPH Sustainable Process Heat, the addition of Bueno Analytics t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom